🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

CRT 2025 was busy and impactful! Thanks to Dr. Ron Waksman for the invite! Honored to present the latest update on Innovalve TMVR EFS (thanks to Dr. Rihal) and thrilled to be a runner-up in Best Cardiovascular Innovations for Laplace TTVR EFS! Exciting times in transcatheter

Great job by Bassim El-Sabawi, MD in putting this together. Now we need prospective data!

Thanks Aniket! Looking forward to learning everything about cardigenic shock at Houston Shock Symposium

Exciting day at VUMC! Successfully completed the FIRST case using the new Innovalve TMVR delivery system as part of the EFS. Grateful for the trust in our team! Shout out to Natalie Jackson, Melissa Long, and our clinical, research and cath lab teams for making this possible!

Brilliant presentations by current fellow Bassim El-Sabawi, MD and previous structural fellow Keniel, M.D. at #ACC25 on all things structural. Great to see so many friends doing amazing things Abdallah El Sabbagh Nadia Sutton R. Jay Widmer Dhaval Kolte, MD, PhD American College of Cardiology

So great to be a part of Houston Shock Symposium 2025 and discussing role of TAVR in obstructive shock and may be even EARLY TAVR prior to development of shock Abhijeet Dhoble Vanderbilt Structural Heart & Valve Center Ran Lee, MD, FACC Aniket Rali, MD, FACC, FCCP Ricky Hansra, MD 🫀

Do you know your state's regulations regarding radiation exposure/protection for procedures requiring fluoroscopy? Great study by Amit N. Vora, MD MPH showing variation across states. SCAI MyJSCAI Binita Shah Prashant Kaul sciencedirect.com/science/articl…

Historic day with FDA approval of balloon-expandable TAVR for asymptomatic severe Aortic stenosis! It was a privilege to be involved in the EARLY TAVR trial that formed the basis of this. More data coming out today at #SCAI2025 on age stratified outcomes from the trial

Pushing the boundaries in tricuspid therapy with two more successful #Trisol TTVR cases last week - making us the top enroller in EFS alongside Piedmont. Excited about the cutting-edge options we can offer for tricuspid regurgitation at VUMC. #StructuralHeart #Innovation #TR

Are you passionate about valve disease? Join us at NY Valves 2025 for cutting-edge devices, groundbreaking data, and world-class education. Don’t miss the heart of innovation! #NYValves2025 #Cardiology #ValveDisease

Severe TR—before or after transseptal MViV—is a prognostic signal. In >5,000 patients, residual severe TR at 30 days was linked to significantly higher 3-year mortality. Interestingly, mortality curves diverge after 1 year (timeline used in most pivotal trials). TR is not a

Sharing our early experience with T-TEER in patients with ESRD — a group often excluded from trials. Encouraging outcomes and zero 1-year mortality suggest they deserve a closer look. Congrats to rising star Dr. Lamiya Rodriguez - Applying for cardiology this year!

Presented new data at #NYVALVES2025 highlighting the impact of Trisol TTVR in patients with severe tricuspid regurgitation (TR): ✅ Significant improvement in RV function and RV-PA coupling ✅ Excellent early outcomes in 4 patients with severe RV dysfunction — a notoriously

Had an amazing time at #NYValves2025 Undoubtedly, the best meeting for valve enthusiasts and it keeps getting better every year! Looking forward to 2026! David J. Cohen, MD, MSc